| Title |
A Phase Ib/III Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients with Locally Advanced or Metastatic HR+ /HER2- Breast Cancer Who Failed Standard of Care Therapies |
| Description |
It is a Phase Ib/III study to evaluate the efficacy and safety of the combination therapy with afuresertib plus fulvestrant (afuresertib/placebo plus fulvestrant in Phase III) in patients with HR+/HER2- breast cancer who have failed 1 to 2 prior lines of endocrine therapy with/without a CDK4/6 inhibitor (up to 1 therapy), and/or chemotherapy (up to 1 chemotherapy) as described in the inclusion criteria. |
| Organism |
Homo sapiens |
| Data Type |
Metabolome Data by Mass Spectrometry (MS) |
| Data Accessibility |
Controlled-access |
| BioProject |
PRJCA012446 |
| Release Date |
2022-11-04 |
| Submitter |
Binghe Xu (xubinghe@csco.org.cn) |
| Organization |
Cancer Hospital, Chinese Academy of Medical Sciences |
| Submission Date |
2022-10-12 |